Company news

Kamada Ltd. news in 2026

Kamada Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026

November 2, 2026

Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026

October 19, 2026

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

October 6, 2026

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

September 17, 2026

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026

Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

August 12, 2026

Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026

August 5, 2026

Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies

July 20, 2026

Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting

July 13, 2026

Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory

June 1, 2026

Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year

May 13, 2026

Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026

May 6, 2026

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

March 30, 2026

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas

March 25, 2026

Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

March 10, 2026

Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

March 10, 2026

Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

March 3, 2026

Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio

January 13, 2026

Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance

January 6, 2026

Calls in 2026

Decks in 2026